| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395294 | HARROW EYE | Method of visualization of the vitreous during vitrectomy |
Jan, 2020
(4 years ago) | |
| US8211880 | HARROW EYE | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Mar, 2029
(4 years from now) | |
| US8128960 | HARROW EYE | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Dec, 2029
(5 years from now) | |
Triesence is owned by Harrow Eye.
Triesence contains Triamcinolone Acetonide.
Triesence has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Triesence are:
- US6395294
Triesence was authorised for market use on 29 November, 2007.
Triesence is available in injectable;intravitreal dosage forms.
Triesence can be used as use for delineation (visualization) during a vitrectomy surgical procedure, treatment of ophthalmic disorders.
The generics of Triesence are possible to be released after 17 December, 2029.
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 29 November, 2007
Treatment: Use for delineation (visualization) during a vitrectomy surgical procedure; Treatment of ophthalmic disorders
Dosage: INJECTABLE;INTRAVITREAL
TRIESENCE family patents
